Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

A synthetic hexapeptide that mimics ghrelin to stimulate growth hormone release from the pituitary gland via GHS receptors.

Quick Stats
Studies 230
Trials 1
Formula C45H55N9O6
Clear All
Utility 3
pubmed Nov 6, 2007

GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia.

Granado. Miriam M; Martín. Ana Isabel AI; López-Menduiña. María M; López-Ca...

In rats given a bacterial toxin that normally hurts the liver, the peptide GHRP-2 (a ghrelin‑like compound) lowered liver enzymes, reduced harmful nitric oxide, cut down inflammatory TNF‑alpha, and boosted IGF‑I levels, indicating it protected the liver. The effect seemed to come from actions on liver support cells rather than the liver cells themselves.

Utility 3
pubmed 1998

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.

Johansen. P B PB; Hansen. K T KT; Andersen. J V JV; Johansen. N L NL

In rats, the peptide ipamorelin and related growth‑hormone‑releasing peptides stay in the blood longer than GHRP‑6 and are mostly cleared in urine. When sprayed into the nose, about 20% of ipamorelin and roughly 50% of GHRP‑2 get into the bloodstream, showing that nasal delivery can work for these peptides.

Utility 3
pubmed May 30, 2007

Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model.

Veldhuis. Johannes D JD; Keenan. Daniel M DM; Bowers. Cyril Y CY

The study shows that in healthy women, getting older sharply cuts down how much growth hormone (GH) is released in bursts, even when estrogen levels are kept constant. Both single shots and continuous infusions of GHRP‑2 (a GH‑releasing peptide) produce much smaller GH spikes in post‑menopausal women compared to younger women.

Utility 3
pubmed 1999

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Arvat. E E; Di Vito. L L; Lanfranco. F F; Broglio. F F; Giordano. R R; Benso. A A; Muccioli. G P GP;...

In a small study of healthy volunteers, the synthetic octapeptide Tyr‑Ala‑HEX boosted growth hormone (GH) just as well as the known GH‑secretagogues Hexarelin and GHRP‑2, and it also raised prolactin, ACTH, and cortisol to similar levels. This shows Tyr‑Ala‑HEX works like the other peptides but the study used an IV dose (2 µg/kg) that isn’t typical for everyday use.

Utility 3
pubmed Feb 1, 2002

GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein.

Tschöp. Matthias M; Statnick. Michael A MA; Suter. Todd M TM; Heiman. Mark L ML

In mice, the ghrelin‑like peptide GHRP‑2 makes you eat more and store extra fat even when a key appetite hormone (NPY) is missing. The weight gain seems to be driven partly by another brain protein called AGRP. This shows that ghrelin‑receptor drugs can push the body into a positive energy balance and could be useful for conditions where people lose weight, but the study is in rodents, not humans.

Utility 3
pubmed 2005

Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy.

Veldhuis. Johannes D JD; Keenan. Daniel M DM; Mielke. Kristi K; Miles. John M JM; Bowers. Cyril Y CY

In healthy older men, giving testosterone raises their natural GH and IGF‑1 levels, but it doesn't make the GH‑releasing peptide GHRP‑2 work any better. The peptide still boosts GH the same amount whether testosterone is present or not.

Utility 3
pubmed Dec 1, 2002

Growth hormone-releasing peptide-2 reduces inward rectifying K+ currents via a PKA-cAMP-mediated signalling pathway in ovine somatotropes.

Xu. Ruwei R; Zhao. Yufeng Y; Chen. Chen C

In sheep pituitary cells that make growth hormone, the peptide GHRP‑2 lowers a specific potassium current (Kir) by activating the PKA‑cAMP pathway, which makes the cells more electrically active and helps release growth hormone. This effect is blocked if PKA is inhibited, but not by blocking PKC.

Utility 3
pubmed 2001

Direct modification of somatotrope function by long-term leptin treatment of primary cultured ovine pituitary cells.

Roh. S G SG; Nie. G Y GY; Loneragan. K K; Gertler. A A; Chen. C C

A lab study on sheep pituitary cells found that leptin, a hormone linked to body fat, lowers the cells' production of growth hormone (GH) and makes them less responsive to the usual GH‑stimulating signal (GHRH). At the same time, leptin increases the cells' sensitivity to GHRP‑2, a peptide that also triggers GH release, and actually boosts the GH response to GHRP‑2. This suggests GHRP‑2 might help offset the GH‑suppressing effects of high leptin levels.

Utility 3
pubmed 2004

Dual secretagogue drive of burst-like growth hormone secretion in postmenopausal compared with premenopausal women studied under an experimental estradiol clamp.

Erickson. Dana D; Keenan. Daniel M DM; Mielke. Kristi K; Bradford. Kandace K; Bowers. Cyril Y CY; Mi...

The study shows that older (post‑menopausal) women have lower baseline growth hormone (GH) and a weaker GH boost when given GHRP‑2 (or other GH‑releasing combos), even when estrogen levels are kept the same. The drop isn’t because they have fewer GH bursts, but because each burst is smaller, and belly fat also explains part of the difference. In short, age, not just estrogen, makes the GH‑releasing effect of GHRP‑2 weaker.

Utility 3
pubmed Aug 8, 2007

Peripheral estrogen receptor-alpha selectively modulates the waveform of GH secretory bursts in healthy women.

Veldhuis. Johannes D JD; Keenan. Daniel M DM; Bowers. Cyril Y CY

The study shows that estrogen acting through peripheral estrogen‑receptor‑alpha changes the shape of growth‑hormone (GH) release bursts in women. Blocking this receptor or adding estrogen can lengthen or shorten how long a GH burst lasts, and the effect depends on which GH‑stimulating agent (like GHRP‑2) is used.

Utility 3
pubmed 2006

GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.

Salvatori. R R; Serpa. M G MG; Parmigiani. G G; Britto. A V O AV; Oliveira. J L M JL; Oliveira. C R...

Even people who completely lack the normal growth‑hormone‑releasing hormone (GHRH) receptor still show a tiny but real rise in GH when given GHRP‑2 or when they experience a low‑blood‑sugar challenge. Clonidine, another GH‑stimulating drug, didn’t work in these patients.

Utility 3
pubmed 2004

Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.

Bowers. Cyril Y CY; Granda. Ramona R; Mohan. Subburaman S; Kuipers. Jonathan J; Baylink. David D; Ve...

In healthy older men and women, a 30‑day continuous sub‑cutaneous infusion of the peptide GHRP‑2 at a low dose (about 1 µg per kg body weight per hour) kept growth hormone pulses high and raised IGF‑I and its binding proteins, without any safety problems. The study also showed that giving GHRP‑2 together with GHRH works better than either alone, especially in older women.

Utility 3
pubmed Apr 3, 2007

Tripartite control of growth hormone secretion in women during controlled estradiol repletion.

Veldhuis. Johannes D JD; Cosma. Mihaela M; Erickson. Dana D; Paulo. Remberto R; Mielke. Kristi K; Fa...

The study shows that, even when estrogen levels are kept the same, older women (post‑menopausal) release far less growth hormone (GH) than younger women after being given GHRP‑2, GHRH, or arginine. Their GH response drops to about one‑third of that seen in younger women, and the usual ranking of which peptide works best (GHRP‑2 being strongest) disappears. More belly fat predicts a weaker GH boost from arginine, while higher IGF‑I levels predict a stronger response to GHRP‑2 and GHRH.

Utility 3
pubmed Apr 5, 2005

Joint mechanisms of impaired growth-hormone pulse renewal in aging men.

Veldhuis. Johannes D JD; Iranmanesh. Ali A; Bowers. Cyril Y CY

The study shows that as men get older, their bodies become less able to shut off growth hormone (GH) after a spike, which means the natural high‑amplitude GH bursts get weaker. In younger men, higher IGF‑I levels make this shut‑off stronger, leading to bigger GH pulses. The ghrelin‑mimic peptide GHRP‑2 can temporarily override this feedback, but its effect varies with age and IGF‑I levels.

Utility 3
pubmed 2001

Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.

Deghenghi. R R; Papotti. M M; Ghigo. E E; Muccioli. G G; Locatelli. V V

The study shows that some synthetic somatostatin drugs (like octreotide, lanreotide, and vapreotide) can bind to the same receptor in the pituitary that GHRP‑2 and other growth‑hormone‑releasing peptides use. Natural somatostatin itself does not do this, but the octapeptide versions do, meaning they could block or alter the effects of GHRP‑2.

Utility 3
pubmed Apr 3, 2006

Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse.

Fintini. Danilo D; Alba. Maria M; Schally. Andrew V AV; Bowers. Cyril Y CY; Parlow. A F AF; Salvator...

In mice that lack the natural hormone that tells the pituitary to release growth hormone, giving a synthetic GHRH drug (JI-38) helped the pituitary grow, and adding the GHRP‑2 peptide on top made the animals taller and heavier than GHRH alone. However, GHRP‑2 by itself could not trigger a growth‑hormone spike unless some GHRH was present.

Utility 3
pubmed 2001

E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.

Anderson. S M SM; Wideman. L L; Patrie. J T JT; Weltman. A A; Bowers. C Y CY; Veldhuis. J D JD

A short 6‑23 day course of oral estradiol (E2) in post‑menopausal women made the growth‑hormone‑releasing peptide‑2 (GHRP‑2) trigger a bigger GH spike, even when the body’s normal feedback was trying to suppress GH. The effect was specific to GHRP‑2; estrogen didn’t change the response to GHRH or the body’s own GH pulses.

Utility 3
pubmed 2001

Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.

Anderson. S M SM; Shah. N N; Evans. W S WS; Patrie. J T JT; Bowers. C Y CY; Veldhuis. J D JD

In healthy post‑menopausal women, taking a short course of oral estradiol (about 2 mg per day for 1‑2 weeks) makes the body release a lot more growth hormone when a GHRP‑2 injection is given. The hormone boost is especially strong at higher GHRP‑2 doses, and the overall sensitivity to the peptide improves.

Utility 3
pubmed 2000

A simple test for growth hormone deficiency in adults.

Mahajan. T T; Lightman. S L SL

The study shows that a short test using the brain hormone‑releasing factor GHRH together with a low dose of the synthetic peptide GHRP‑2 can safely trigger a measurable growth‑hormone (GH) surge. Compared to the traditional insulin tolerance test, this GHRH/GHRP‑2 combo is easier, has no side‑effects, and correctly identified GH‑deficient adults with about 79% sensitivity and perfect specificity at a cut‑off of 17 mU/L.